Julphar Bangladesh launched Nexanib, a new class of drug of targeted therapy for HCC
After successful introduction of Hepatitis C product in our virology portfolio from 2015, we are the consistent leader in this Hepatitis C market. Now, Julphar Bangladesh has launched another new class of drug of targeted therapy the name is Nexanib 200 (Sorafenib 200 mg) tablet for the treatment of Hepatocellular Carcinoma (HCC).
Targeted therapy for HCC
♦ First line therapy in advance HCC
♦ Prolongs overall survival